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Purpose: To evaluate the usefulness of dynamic contrast-enhanced ultrasonography (DCE-US) 
in the early quantification of hemodynamic change following administration of the vascular 
disrupting agent (VDA) CKD-516 using a rabbit VX2 liver tumor model.
Methods: This study was approved by our institutional animal care and use committee. Eight VX2 
liver-tumor-bearing rabbits were treated with intravenous CKD-516, and all underwent DCE-
US using SonoVue before and again 2, 4, 6, and 24 hours following their treatment. The tumor 
perfusion parameters were obtained from the time-intensity curve of the DCE-US data. Repeated 
measures analysis of variance was performed to assess any significant change in tumor perfusion 
over time. Relative changes in the DCE-US parameters between the baseline and follow-up 
assessments were correlated with the relative changes in tumor size over the course of seven 
days using Pearson correlation. 
Results: CKD-516 treatment resulted in significant changes in the DCE-US parameters, including 
the peak intensity, total area under the time-intensity curve (AUCtotal), and AUC during wash-out 
(AUCout) over time (P<0.05). Pairwise comparison tests revealed that the AUCtotal and AUC during 
wash-in (AUCin) seen on the two-hour follow-up were significantly lower than the baseline values 
(P<0.05). However, none of early changes in the DCE-US parameters until 24-hour follow-up 
showed a significant correlation with the relative changes in tumor size during seven days after 
CKD-516 treatment.
Conclusion: Our results suggest that a novel VDA (CKD-516) can cause disruption of tumor 
perfusion as early as two hours after treatment and that the therapeutic effect of CKD-516 
treatment can be effectively quantified using DCE-US. 
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Introduction
Tumor neovascularization is a critical step for tumor growth and 
results in structurally and functionally abnormal tumor blood vessels, 
which are then worthwhile targets for anti-cancer treatment [1,2]. 
Recently, anti-vascular therapy has been widely investigated as a 
promising approach for cancer treatment [3-5]. According to the 
action mechanism, anti-vascular drugs can be divided into two 
categories, that is, an anti-angiogenic agent which inhibits the out-
growth of new vessel formation from pre-existing vessels, and a 
vascular disrupting agent (VDA) which destroys the established 
tumor vessels [6]. 
Monitoring the therapeutic efficacy of anti-vascular therapy as 
well as the early prediction of tumor response is of great importance, 
as it may quicken making a go or no-go decision for each patient, 
which will maximize the benefits and minimize the drawbacks of 
treatment [7]. Although tumor size change has traditionally been 
used to assess the cancer treatment effects of chemotherapy, size 
measurement may be insensitive or delayed chronologically during 
the monitoring of anti-vascular treatment and thus cannot be relied 
upon to accurately and promptly indicate the therapeutic effect 
[8]. Current studies have reported the usefulness of quantitative 
imaging methods including dynamic contrast-enhanced magnetic 
resonance imaging (DCE-MRI), DCE computed tomography (DCE-CT), 
and DCE ultrasound for monitoring the therapeutic effect of anti-
vascular treatment, which can demonstrate hemodynamic changes 
noninvasively and longitudinally [3,6]. Among those imaging 
methods, DCE ultrasonography (DCE-US) has several advantages 
over DCE-MRI and DCE-CT, as it can be easily performed repeatedly 
at low cost and without patient exposure to ionizing radiation, and 
the ultrasound contrast agent is a purely intravascular marker of 
blood flow and perfusion that is not confounded by extravascular 
diffusion [7,9]. 
CKD-516 is a novel, small-molecule VDA which acts by inhibiting 
tubulin polymerization, causing rapid disruption of established tumor 
vessels by microtubule destabilization and cell apoptosis by cell-cycle 
arrest [10]. CKD-516 is in the ongoing phase I clinical trial period; 
therefore, appropriate timing of imaging to determine its therapeutic 
efficacy is critical. A recent preclinical study using DCE-MRI revealed 
a significant decrease in the tumor perfusion parameters seen at 
the four-hour follow-up and a significant recovery seen at the 48-
hour follow-up following the CKD-516 treatment [11]. However, no 
previous study has shown serial perfusion changes induced by CKD-
516 using DCE-US or a correlation between the DCE-US parameters 
and the tumor response. 
Therefore, this preclinical study using rabbit VX2 liver tumor 
models investigated the usefulness of DCE-US in the early 
quantification of hemodynamic changes seen serially after 
administration of a novel VDA (CKD-516) and investigated whether 
DCE-US parameters would be early predictors of the tumor response. 
Materials and Methods
Animal Model and Experiment Schedule
This study was approved by the Animal Care and Use Committee 
of Seoul National University Hospital. Fourteen male New 
Zealand White rabbits weighing between 2.5 and 3.5 kg were 
used. Prior to tumor implantation, the animals were sedated by 
intravenous injection of 5 mg/kg of a 1:1 combination of tiletamine 
hydrochloride and zolazepam (Zoletil; Virbac, Carros, France) and 
xylazine hydrochloride (Rompun 2%; Bayer Korea, Seoul, Korea). 
Through a midline abdominal incision, the left lobe of the liver was 
exposed and an approximately 5-mm tunnel was created in the 
subcapsular area of the left lobe of the liver. Then, approximately 
1-mm
3 minced pieces of freshly harvested VX2 carcinoma tissue 
were locally implanted in the liver via the tunnel. The VX2 liver 
tumors were incubated for 10 to 15 days after tumor implantation 
and prior to the baseline imaging. Fourteen tumor-carrying rabbits 
were randomly divided into the CKD-516-treated group (n=8) and 
the control group (n=6). CKD-516 solution was administered to 
the treated group immediately following the baseline ultrasound 
imaging. For each rabbit of the CKD-516-treated group (n=8), 
follow-up DCE-US studies were performed at two, four, six, and 24 
hours following CKD-516 administration. At the baseline and seven-
day follow-up examinations, the longest tumor dimensions were 
measured on ultrasound. To evaluate the reproducibility of the DCE-
US parameters, the control group rabbits (n=6) underwent repeated 
DCE-US studies at two-hour intervals, that is, at baseline and the 
two-hour follow-up. 
Vascular Disrupting Agent (CKD-516) Preparation
CKD-516 (Chong Kun Dang Pharm, Seoul, Korea) is a novel water-
soluble VDA which acts by inhibiting tubulin polymerization [12]. 
For each rabbit in the treated group, CKD-516 solution, which was 
prepared by dissolving CKD-516 at a dose of 9 mg/m
2 body surface 
area in 5 mL of normal saline, was administered by slow intravenous 
injection over the course of five minutes via the auricular vein. 
DCE-US Study 
For all of the DCE-US studies, we used SonoVue (Bracco, Milano, 
Italy), which is a second-generation ultrasound contrast agent [13]. 
In each DCE-US study, a rabbit with a VX2 liver tumor was injected 
with a 1.0-mL bolus of SonoVue followed by 2.0 mL of a normal 
saline flush through the auricular vein. Ultrasound examinations Ijin Joo, et al.
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were performed using an AplioXG ultrasound scanner (Toshiba 
Medical Systems, Otawara, Japan) using a 805AT linear probe (6-12 
MHz, mean 9 MHz). A fundamental B-mode ultrasound was used to 
detect the VX2 liver tumors and to measure the longest dimension 
of the tumor. For the DCE-US imaging, the vascular recognition 
imaging mode with a low mechanical index of 0.06 was used, as 
it could detect the signal generated by microbubbles [14]. DCE-US 
images were continuously recorded beginning at the time of the 
SonoVue injection and for three additional minutes (four frames per 
second). 
DCE-US Imaging Data Analysis
Quantitative DCE-US parameters were obtained using the dedicated 
software CHI-Q (Toshiba Medical Systems). By manually drawing a 
region of interest (ROI) along the margin of the tumor at a selected 
frame, the ROI would then be auto-positioned throughout all of 
the study images. If there were changes in the tumor position 
due to respiratory motion during the exam, we could adjust the 
ROI at a particular frame and the software would interpolate the 
ROI positions between two frames of the different ROIs and then 
automatically retrack the later ROI [14]. From the time-intensity 
curves of the ROIs, which were generated by analyzing the three-
minute raw linear data of the DCE-US imaging, the following 
perfusion parameters were obtained: peak intensity (PI), slope 
coefficient of the wash-in, time to peak intensity (TTP), mean transit 
time (MTT), total area under the time-intensity curve (AUCtotal), AUC 
during the wash-in (AUCin), and AUC during the wash-out (AUCout). 
Histologic Analysis
Immediately after the seventh day of follow-up imaging, all of 
the rabbits were sacrificed under deep anesthesia induced by an 
intravenous injection of 5 mL of KCl, after which they were frozen 
at -70˚C. Pathologic specimens were sectioned in the transverse 
plane at 1-mm intervals and a representative microscopic section 
was selected that included the longest dimension of the tumor. 
The necrotic fraction (NF) was defined as the division of the area 
of tumor necrosis by the area of the total tumor. The NF for each 
tumor can be calculated by manually drawing regions of interest to 
circumscribe the outer tumor borders and regions of tumor necrosis 
on hematoxylin and eosin (H&E)-stained tissue sections using 
ImageJ analysis software (http://rsb.info.nih.gov/ij). To determine 
the histological vascular tumor parameters, hot spots, referring to 
higher vascular density areas than those in the rest of the tissue on 
the CD31-stained tissue sections, were chosen at low magnification   
(×40) and CD31-stained vessels were counted at high magnification 
(×200, 0.544 mm
2). The mean of three measurements in the hot 
spot areas was used as the mean vessel density (MVD) of the tumor. 
Statistical Analysis 
To assess the reproducibility of the DCE-US parameters, the 
measured values seen on baseline and the two-hour follow-up 
in the control group (n=6) were compared and corresponding 
coefficients of variation (CVs) within the subjects were calculated. 
CVs of ≤10%, 10%-25%, and ≥25% were considered to be of 
good, moderate, and poor reproducibility, respectively [15]. In the 
CKD-516-treated group (n=8), repeated measures analysis of 
variance (ANOVA) was performed to determine what change in 
tumor perfusion would be significant at different points in time, 
and when significant differences were found, Bonferroni-adjusted 
pairwise comparisons were performed. In order to evaluate whether 
DCE-US parameters could be used as early predictive indicators of 
the tumor response, the relative percentage changes in the DCE-
US parameters between the baseline and the follow-up checks until 
24 hours were correlated with the relative percentage changes in 
tumor size during seven days using Pearson correlation in the CKD-
516-treated group. The histological features of the control and the 
treated group, including the NF and MVD, were compared using the 
Student t-test. A P-value less than 0.05 was regarded as statistically 
significant. All statistical analyses were performed using MedCalc 
ver. 12.4.0.0 (MedCalc Software, Ostend, Belgium).
Results
Reproducibility of DCE-US Parameters
In the six control group rabbits, the PI, TTP, AUCtotal, AUCin, and 
AUCout showed moderate reproducibility with CVs of 24.6%, 18.8%, 
17.9%, 16.1%, and 20.9%, respectively, while the slope coefficient 
of the wash-in and MTT showed poor reproducibility with CVs of 
47.7% and 34.8%, respectively. Therefore, we used the five DCE-
US parameters of moderate reproducibility, including PI, TTP, AUCtotal, 
AUCin, and AUCout to assess the serial perfusion change of the VX2 
liver tumor following administration of CKD-516 in the treated 
group. 
Serial Change in DCE-US Parameters after VDA Treatment
The serially measured DCE-US parameters and relative percentage 
changes compared to the baseline values are summarized in Table 
1. After CKD-516 administration, the tumor perfusion parameters, 
including the PI, AUCtotal, AUCin, and AUCout, began to decrease from 
those seen on the initial follow-up (two hours after treatment) by 
more than 70% and remained decreased until the 24-hour follow-
up. The TTP had increased at the 24-hour follow-up by 46.5% 
(from 37.0 to 54.2 sec). Repeated measures ANOVA revealed 
statistically significant differences in the PI, AUCtotal, and AUCout over 
time (from baseline to the 24-hour follow-up; P<0.05) (Figs. 1, 2). Early quantification of hemodynamic change after VDA treatment
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The Bonferroni-adjusted pairwise comparison test revealed that 
the AUCtotal and AUCin, as seen on the two-hour follow-up, were 
significantly lower than the baseline values (P<0.05). 
Early Prediction of Tumor Response to VDA Treatment Using 
DCE-US Parameters 
Among the eight rabbits in the treated group, one died after the 24-
hour follow-up. Therefore, the DCE-US parameters of the remaining 
seven rabbits were evaluated in order to determine the early 
predictors of tumor response to VDA treatment. The tumor response 
was assessed in terms of the change in tumor size during the seven-
day experimental period. The longest tumor dimension was the 
mean±SD of 11.0±5.3 mm at baseline and 16.9±5.8 mm seen at 
the seven-day follow-up. The relative change in tumor size during 
A
B
Fig. 1. Dynamic contrast-enhanced ultrasonography (DCE-US) images obtained in the vascular recognition imaging mode and the 
corresponding time-intensity curves of a rabbit VX2 liver tumor. 
A, B. The DCE-US studies performed (A) before and (B) six hours after CKD-516 treatment revealed that CKD-516 treatment induced marked 
decrease in tumor vascularization. Note that the scales of the Y-axis of (A) and (B) differ (ranges of 0.02-1.20×10
-4 and 0.14-5.50 ×10
-5, 
respectively). Ijin Joo, et al.
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the experimental period was 63.5%±37.0%, which did not differ 
significantly from that of the control group (65.4%±39.1%, P> 
0.05). Pearson correlation test demonstrated no relative percentage 
changes in the DCE-US parameters until the 24-hour follow-up 
showed a significant correlation with the relative changes in tumor 
size in the CKD-516-treated group (P>0.05).
Comparison of the Histological Features of the Control 
Group and the Treated Group
The NF of the tumor did not differ significantly between the control 
group (mean±SD of 45.8%±23.2%) and the CKD-516-treated 
group (36.2%±23.2%, P>0.05). Regarding the MVD, there was no 
statistically significant difference between that of the control group 
(19.7±8.1) and the CKD-516-treated group (11.8±4.9, P>0.05) (Fig. 
3). 
Table 1. Serial measurements and relative changes of DCE-US parameters in the CKD-516-treated group
Variable PI (au) TTP (sec) Areatotal (au) Areain (au) Areaout (au)
Baseline 3.46±2.42 37.0±21.9 251.8±135.8 61.4±24.3 194.1±120.2
2-Hour 0.91±0.83 (-73.7) 36.2±15.7 (-2.2) 66.1±53.3 (-73.7) 17.6±11.7 (-71.3) 48.6±42.1 (-74.9)
4-Hour 1.76±1.07 (-49.1) 43.0±26.8 (16.2) 132.5±93.2 (-47.4) 42.3±38.4 (-31.1) 90.2±60.0 (-53.5)
6-Hour 1.24±0.90 (-64.2) 34.2±17.3 (-7.6) 95.1±60.8 (-62.2) 29.2±23.5 (-52.4) 65.9±38.4 (-66.0)
24-Hour 1.05±1.05 (-69.7) 54.2±37.5 (46.5) 59.8±37.9 (-76.3) 18.9±12.9 (-69.2) 40.9±27.2 (-78.9)
P-value
a)  0.01 0.45  <0.01 0.07  <0.01
Values are presented as mean±SD (relative percentage change compared with the baseline value). 
DCE-US, dynamic contrast-enhanced ultrasonography; PI, peak intensity; TTP, time to peak intensity. 
a) Repeated measures ANOVA.
Discussion
Our study results demonstrate that DCE-US was useful for measuring 
the serial, quantitative changes in the tumor perfusion in a rabbit 
VX2 liver tumor model after a novel VDA (CKD-516) administration. 
As a potent VDA, CKD-516 disrupted the tumor perfusion as soon 
as two hours after administration and thus resulted in a significant 
decrease in the DCE-US parameters, including the PI, AUCtotal, AUCin, 
and AUCout, during the time from baseline to the 24-hour follow-up 
(P<0.05), and pairwise comparison tests revealed that the AUCtotal 
and AUCin, as seen at the two-hour follow-up, were significantly 
lower than the baseline values (P<0.05).  
In this study using liver tumor models, among the DCE-US 
parameters, the PI, TTP, AUCtotal, AUCin, and AUCout showed moderate 
reproducibility with CVs of 10%-25%. As the reproducibility of 
the measured parameters is one of the most important features 
of longitudinal studies, those DCE-US parameters can be expected 
to be valuable imaging biomarkers for monitoring the therapeutic 
effect of VDAs [16]. When we performed serial follow-up DCE-US 
at two, four, six, and 24 hours after CKD-516 administration in a 
rabbit VX2 liver tumor model, a maximal decrease (about-70%) 
in perfusion parameters including PI, AUCtotal, AUCin, and AUCout 
was found at the time of the two-hour follow-up. As VDAs induce 
vascular collapse and destroy pre-existing vessels, VDA effects 
typically occur within a few hours, while anti-angiogenic drug effects 
occur after days to weeks [4,17]. Therefore, an early and optimal 
follow-up imaging schedule is critical for evaluating the therapeutic 
efficacy of VDA. Until now, there have been only a few studies 
reporting the imaging timing after VDA treatment. Lavisse et al. 
[18] reported that that the maximum effect of the VDA, AVE8062, 
was observed at the six-hour follow-up, which differed from the 
one-hour or 24-hour follow-ups using DCE-US in a subcutaneous, 
melanoma-bearing mouse model. In our study, following CKD-516 
treatment, the serially measured PI, AUCtotal, and AUCout decreased 
significantly over time (P<0.05) and post-hoc analysis revealed 
Fig. 2. Serial time-intensity curves in one study subject before, 
two hours after, and 24 hours after CKD-516 administration. After 
the CKD-516 treatment, both the peak intensity (PI) and the area 
under the time-intensity curve (AUC) were markedly decreased at 
the two-hour follow-up compared to the baseline values (from 4.2 
to 0.9 au for the PI; from 326.0 to 59.9 au for the AUCtotal), whereas 
the time to the peak increased at the 24-hour follow-up (from 22.1 
to 46.6 sec). 
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helpful for predicting the long-term outcomes of anti-angiogenic 
drug treatment, whereas only a few previous studies have suggested 
a useful predictor of tumor response for VDA treatment [4,22-24]. 
The histological features of the tumor, including the NF and MVD, 
seen at the time of the seven-day follow-up, showed no statistically 
significant differences in the control group and the CKD-516-treated 
group. A previous study which compared the histologic findings of 
VX2 carcinomas in a rabbit tumor model between control and CKD-
516-treated groups at four-hour and 36-hour follow-up checks, 
demonstrated that the degree of tumor necrosis was significantly 
greater in the treated group than in the control group at the time 
of the 36-hour follow-up [11]. The change in the degree of tumor 
necrosis at different points in time could be explained by the action 
mechanism and duration of the VDA, as it rapidly disrupts tumor 
vessels, thus causing central tumor necrosis. Then the drug effect 
usually disappears within 1-2 days and tumor regrowth may occur 
from the periphery of the tumor [3,25]. Regarding the MVD, a 
previous study also did not show significant difference between the 
control and the CKD-516-treated groups at four-hour and 36-hour 
follow-ups, whereas the DCE-MR parameters, similar to our study 
results with DCE-US, significantly decreased both at four-hour and 
36-hour follow-ups after CKD-516 treatment [11]. This discrepancy 
between the early perfusion change by the VDA and MVD might be 
explained by that the main cause of the decreasing tumor perfusion 
within a few hours after VDA treatment may be due to vascular 
collapse induced by VDA, rather than decrease in MVD [18]. In 
that the AUCtotal and AUCin were significantly lower at the two-hour 
follow-up than the baseline values (P<0.05). Although there was 
no statistical significance (P>0.05), the TTP had increased at the 
24-hour follow-up by 46.5%. Our results are in good agreement 
with previous DCE-US studies evaluating the therapeutic effects of 
other VDAs, specifically, that AVE8062 induced a marked decrease 
in the PI and an increase in the TTP as seen at a six-hour follow-
up [18], and 5, 6-dimethylxanthenone-4-acetic acid resulted in a 
significant decrease in the AUC as seen at a 24-hour follow-up [19]. 
As VDAs reduce tumor vascularity and the DCE-US contrast agent 
(SonoVue) is an intravascular tracer, the signal strength generated 
by microbubbles following VDA treatment should decrease during 
the entire scanning time, and, therefore, the PI and AUC of the time-
intensity curve should decrease [20]. An increase in the TTP indicates 
slower penetration of the contrast media into the tumor, and a 
prolonged presence of TTP after VDA treatment would be explained 
by the reduction of tumor blood vessels, based on the histological 
findings of previous studies [18,21].
No significant correlation was found between the relative changes 
in DCE-US parameters at any of the points in time and the relative 
change in tumor size over the course of the seven days after CKD-
516 treatment. In other words, in our study, none of the DCE-US 
parameters were shown to be early predictors of the tumor response. 
Several studies have shown that the quantitative parameters derived 
using functional imaging techniques such as DCE-MR, DCE-US, and 
[18F] fluorodeoxyglucose positron emission tomography would be 
Fig. 3. Immunohistochemistry of the VX2 liver tumors showing microvessels at a 7-day follow-up. 
On the microscopic specimen (CD31 staining, ×200). A. A tumor in the CKD-516-treated group shows a smaller number of microvessels 
(arrowheads). B. Another tumor in the control group shows a greater number of CD31-stained microvessels (arrowheads) and more 
prominent septa (asterisks). 
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addition, as the VDA effect would disappear within one or two days 
and the peripheral tumor usually survives and regrows, the histologic 
features at the seven-day follow-up might not be expected to differ 
between the control and treated-groups, just as we found in our 
study [3,4]. 
This study has several limitations. First, each DCE-US study was 
performed using the two-dimensional technique after the operator 
selected an imaging plane including the longest dimension of the 
tumor, therefore, the imaging planes of the serial DCE-US might not 
be identical. A three-dimensional study including the entire tumor 
volume would be required in order to overcome this limitation [26]. 
Second, as we only evaluated the histologic features on the seven-
day follow-up, any early changes in the DCE-US parameters and 
corresponding histologic changes could not be correlated.
In conclusion, our results suggest that a novel VDA (CKD-516) 
treatment causes disruption of tumor perfusion as early as 2 hours 
after treatment and the early hemodynamic change induced by 
CKD-516 treatment can be effectively quantified using DCE-US.
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